Availability rate of new oncology medicines in Europe 2024, by country

This statistic displays the share of oncology medicines approved by the European Medicines Agency (EMA) between 2019 and 2022 which were available to patients in selected European countries as of January 5, 2024. According to the data, 96 percent of approved oncology medicines were available to patients in Germany, followed by 92 percent in Switzerland.

Percentage of oncology medicines approved by the EMA available to patients in Europe as of 2024, by country

Characteristic	Share of medicines available
Germany	96%
Switzerland	92%
Austria	85%
Italy	83%
Denmark	75%
Czech Republic	75%
Portugal	73%
Greece	71%
France	67%
Luxemburg	63%
Spain**	60%
Sweden	56%
England	56%
Finland	54%
Cyprus*	54%
Bulgaria	54%
Belgium	54%
Poland	52%
Slovenia	50%
Scotland	50%
Norway	44%
Netherlands	44%
Iceland	44%
Hungary	33%
Ireland	29%
Croatia*	29%
Latvia	21%
Slovakia	19%
Romania	19%
Estonia	17%
North Macedonia*	15%
Serbia	13%
Bosnia and Herzegovina*	8%
Lithuania	6%
Turkey	4%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

June 2024

More information

Region

Europe

Survey time period

as of January 5, 2024

Supplementary notes

48 oncology medicines were approved by the European Medicines Agency between 2019 and 2022.
In most countries, availability equates to granting of access to the reimbursement list, except in DK, FI, LU. NO, SE some hospital products are not covered by the general reimbursement scheme.
* Country did not complete a full dataset and therefore availability may be unrepresentative.
** In Spain, the WAIT analysis does not identify those medicinal products being accessible earlier in conformity with Spain's Royal Decree 1015/2009 relating to Medicines in Special Situations.

Citation formats